HAB Pharma's Strategic Expansion in Dehradun

HAB Pharmaceutical & Research Ltd, a leader in the pharmaceutical manufacturing sector, has recently acquired a 10-acre plot in Dehradun, previously owned by Elder Pharmaceuticals Ltd. This acquisition is a pivotal part of HAB Pharma's expansion strategy, aimed at enhancing its manufacturing capabilities to meet the surging demand in the healthcare industry.

Innovating for the Future

With a legacy of innovation since its establishment in 1989 by entrepreneurs KK Agrawal and Sanjiv Garg, HAB Pharma has grown into a powerhouse known for its high-speed production lines and robust manufacturing processes. The new facility in Dehradun is set to house a state-of-the-art Metered Dose Inhaler (MDI) manufacturing unit, catering to the increasing demand for respiratory treatments. Additionally, the company is making strides into biologics, focusing on treatments for autoimmune disorders, a fast-growing segment in advanced healthcare solutions.

Commitment to Quality and Innovation

HAB Pharma operates two world-class facilities in Vasai, Mumbai, and Dehradun, complemented by its sister concern, Signature Phytochemical, which further bolsters its manufacturing presence with three units in Dehradun. The recent inauguration of a beta-lactam injectable facility underscores the company's unwavering commitment to quality and innovation. Renowned for its efficiency and quality, HAB Pharma is a trusted contract manufacturer for major pharmaceutical companies like Zydus Lifesciences and Alkem Laboratories.

With its latest expansion, HAB Pharma is set to redefine pharmaceutical manufacturing in India and beyond, driven by its mission to advance global healthcare standards through innovation, quality, and a steadfast commitment to patient well-being.